G-CSF primary prophylaxis use and outcomes in patients receiving chemotherapy at intermediate risk for febrile neutropenia: a scoping review
Author:
Affiliation:
1. Oncology Medical Affairs, Sandoz Inc, Princeton, NJ, USA
2. Value and Access, Novartis Healthcare Pvt. Ltd, Hyderabad, India
3. Health Economics and Outcomes Research, Novartis Pharmaceuticals, East Hanover, NJ, USA
Funder
Sandoz, Inc
Publisher
Informa UK Limited
Subject
Hematology
Link
https://www.tandfonline.com/doi/pdf/10.1080/17474086.2022.2093712
Reference64 articles.
1. Incidence, cost, and mortality of neutropenia hospitalization associated with chemotherapy
2. Epidemiology of Febrile Neutropenia
3. Cancer-Associated Neutropenic Fever: Clinical Outcome and Economic Costs of Emergency Department Care
4. Costs Associated with Febrile Neutropenia in the US
5. Colony-Stimulating Factors for the Management of Neutropenia in Cancer Patients
Cited by 8 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. The clinical impact of primary granulocyte-colony stimulating factor prophylaxis in children with acute lymphoblastic leukemia who underwent induction chemotherapy;Journal of Microbiology, Immunology and Infection;2024-08
2. Population pharmacokinetic and exposure-toxicity analyses of nab-paclitaxel after pegylated recombinant human granulocyte colony-stimulating factor administration in patients with metastatic breast cancer;Cancer Chemotherapy and Pharmacology;2024-07-31
3. Filgrastim biosimilar (EP2006): A review of 15 years’ post-approval evidence;Critical Reviews in Oncology/Hematology;2024-04
4. The frequency of regimens associated with high risk of febrile neutropenia and the incidence of dose-limiting neutropenia among patients receiving cytotoxic therapy for malignancies: the FLAME study results;Journal of Modern Oncology;2023-12-10
5. The occurrence and risk factors of chemotherapy-induced neutropenia in patients with breast cancer not receiving primary G-CSF prophylaxis;ecancermedicalscience;2023-11-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3